DysPIA: A Novel Dysregulated Pathway Identification Analysis Method

Limei Wang¹,²,³†, Weixin Xie¹†, Kongning Li², Zhenzhen Wang², Xia Li²,³*, Weixing Feng¹* and Jin Li²,³*

¹ College of Intelligent Systems Science and Engineering, Harbin Engineering University, Harbin, China, ² Key Laboratory of Tropical Translational Medicine, Ministry of Education, College of Biomedical Information and Engineering, Hainan Medical University, Haikou, China, ³ College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China

Differential co-expression-based pathway analysis is still limited and not widely used. In most current methods, the pathways were considered as gene sets, but the gene regulation relationships were not considered, and the computational speed was slow. In this article, we proposed a novel Dysregulated Pathway Identification Analysis (DysPIA) method to overcome these shortcomings. We adopted the idea of Correlation by Individual Level Product into analysis and performed a fast enrichment analysis. We constructed a combined gene-pair background which was much more sufficient than the background used in Edge Set Enrichment Analysis. In simulation study, DysPIA was able to identify the causal pathways with high AUC (0.9584 to 0.9896). In p53 mutation data, DysPIA obtained better performance than other methods. It obtained more potential dysregulated pathways that could be literature verified, and it ran much faster (∼1,700–8,000 times faster than other methods when 10,000 permutations). DysPIA was also applied to breast cancer relapse dataset and breast cancer subtype dataset. The results show that DysPIA is effective and has a great biological significance. R packages “DysPIA” and “DysPIAData” are constructed and freely available on R CRAN (https://cran.r-project.org/web/packages/DysPIA/index.html and https://cran.r-project.org/web/packages/DysPIAData/index.html), and on GitHub (https://github.com/lemonwang2020).

Keywords: dysregulated pathway, enrichment analysis, differential co-expression, gene regulation, differential expression, differential variability

INTRODUCTION

Over the past three decades, an amount of high-dimensional biological omics data types have emerged including genomics, sequencing, proteomics, epigenomics, and genome editing (Auffray et al., 2009). A common use of these data is to gather and compare samples from multiple conditions, e.g., disease and non-disease, cancer subtypes, drug sensitivity, and drug resistance, in an attempt to identify some biomarkers to distinguish between different conditions. Currently, the common methods of comparing samples from different conditions were Differential Expression (DE) analysis, Differential Variability (DV) analysis, and Differential Co-expression (DC) analysis (Ho et al., 2008; McKenzie et al., 2016) (Figure 1). In some research, DC gene pair was also called...
FIGURE 1 | Toy example of DE, DV, and DC. (A) The means of gene expression are significantly different between the two conditions, such as case and control, while the variances are similar. (B) The variances of gene expression are significantly different between the two conditions, while the means are similar. (C) The correlation coefficients of the two genes are significantly different between the two conditions.

Compared with gene-level analysis, pathway analysis can help in getting an insight into biological mechanisms, drug response, and disease states (Kanehisa et al., 2012). Classical pathway enrichment analysis methods, such as DAVID (Huang da et al., 2009a,b), were based on overrepresented statistical tests (such as Fisher’s exact test and hypergeometric test) to assess whether DE/DV genes were overrepresented in a predefined pathway. As the most popular one in the second-generation methods, Gene Set Enrichment Analysis (GSEA) (Subramanian et al., 2005) started with ranking all genes according to their DE levels, and then used the weighted Kolmogorov–Smirnov statistic to test whether genes from a prespecified pathway were significantly overrepresented toward the top or bottom of the ranked gene list. The similar strategies were used in gene set analysis (GSA) (Efron and Tibshirani, 2007), Parametric Analysis of Gene set Enrichment (PAGE) (Kim and Volsky, 2005), and Significance Analysis of Function and Expression (SAFE) (Barry et al., 2005). These conventional methods of pathway analysis focused on gene marginal effects in a pathway and ignored gene interactions that may contribute to a phenotype of interest. For two genes in a

dysregulated gene pair. A range of statistical procedures, such as linear modeling (Smyth, 2004), SAM (Tusher et al., 2001), Bayesian methods (Hardcastle and Kelly, 2010; Hardcastle, 2016), and F test (Cui and Churchill, 2003), have been devised for accurate and efficient identification of DE and DV genes. Distinct from DE and DV, the DC methods that emerged to gain insights into the difference in gene–gene relationships between various conditions were gene-pair (regulation) centroid methods rather than individual-gene centroid methods. Currently, most of the DC methods relied on the Pearson correlation coefficient (PCC), such as DiffCorr (Fukushima, 2013), link-based DCEA (Yu et al., 2011), and DGCA (McKenzie et al., 2016). In biological pathways with gene interactions or regulations, DC gene pairs can also be considered as dysregulated gene pairs. The Correlation by Individual Level Product (CILP) was proposed in Lea et al. (2019) article to identify factors associated with interindividual variation in correlation. CILP can be used to estimate the dysregulated status of each gene pair between case and control samples. In the CILP method, there was a unique score for each gene pair in each sample, rather than a summary PCC statistic for a group.
pathway, neither of them may have an effect on a phenotype of interest. However, when they were jointly considered, they may have a significant effect on the studied phenotype due to the gene–gene interaction. In the third generation of pathway analysis methods, such as Signaling Pathway Impact Analysis (SPIA) (Tarca et al., 2009) and Pathway Recognition Algorithm using Data Integration on Genomic Models (PARADIGM) (Vaske et al., 2010), the pathway topology was incorporated into the analysis. However, this gene regulation information (edge) was just used to adjust the gene (node) value in these methods.

Since the measures of these methods are mainly based on individual gene levels, they can be deemed as node (gene)-centric methods. Although these methods have made success in identifying significant biological pathways, the gene-pair relationships have not been fully considered. Obviously, the regulation relationships among genes were also the fundamental components of pathways, and their changes may play an important role in altering the activities of pathways (Liu et al., 2012). The DC-based pathway analysis aimed to identify pathways with more gene regulation differences related to the phenotype of interest. There were several studies focusing on DC-based pathway analysis. However, it is still not fully considered, and some improvements are needed.

Choi and Kendziorski proposed Gene Set Co-expression Analysis (GSCA) to identify differentially co-expressed (DC) gene sets (Choi and Kendziorski, 2009). Pairwise co-expressions were calculated for all the gene pairs within a pathway, then a dispersion index was introduced to quantify the differences between conditions, and samples were permuted across conditions to simulate the null distribution of equivalent correlation between conditions to identify significant DC pathways. The GSCA approach did not require genes to be highly correlated under at least one biological condition, but there were two weaknesses. The first was that the sample sizes of different conditions were not considered while just using the PCC. The second was that pathways were considered as gene sets, but the gene regulations were not considered. For each pathway, all the possible gene pairs were used to calculate the dispersion index.

Rahmatallah et al. (2014) proposed Gene Sets Net Correlations Analysis (GSNCA). It was a multivariate differential co-expression test which accounted for the complete correlation structure between genes. In GSNCA, weight factors related to the eigenvector of the correlation coefficient matrix under specific conditions were assigned to genes in proportion to the genes’ cross-correlations. Samples’ condition labels were permuted to estimate the significant level. The same as GSCA, a pathway was considered as a gene set and the gene regulation relationships were not considered in GSNCA. The correlation coefficient matrix for all the genes in a pathway was used to calculate the weight factor.

Zhang et al. (2009) proposed a gene interaction enrichment analysis method named “Interaction-based Gene Set Analysis” (IB-GSA). It incorporated knowledge of pathways to identify enriched gene interaction effects on a phenotype of interest. In IB-GSA, for each gene pair, the t-test was performed to compare the Pearson correlations between different conditions, and the t statistic was transformed to z score. Then the GSA-like “maxmean” statistic (Efron and Tibshirani, 2007) was adopted to calculate a pathway score that reflected the degree of gene interaction enrichment for the pathway. The “restandardization” permutation method was implied to determine the pathway significance. At last, the estimated significance level was adjusted to account for multiple-hypothesis testing through a standard Benjamini–Hochberg (BH) (Benjamini and Hochberg, 1995) FDR analysis. The same as GSCA and GSNCA, in IB-GSA, a pathway was considered as a gene set and the gene regulation relationships were not considered. The “maxmean” statistic was calculated based on all the possible gene pairs in the pathway.

Han et al. (2015) proposed a mutual information (MI)-based Edge Set Enrichment Analysis (ESEA) method to identify dysregulated pathways. In ESEA, a MI-based Edge Score was calculated for each regulated gene pair in pathways, then GSEA-based enrichment scores for pathways were calculated, the significant P-values were estimated based on permutation, and lastly the BH-FDR analysis was performed to adjust the estimated significance level. In ESEA, the background gene-pair set was not sufficient, the MI-based Edge Score was novel but has less directly biological meaning than the classic correlation coefficient, and the computational speed was extremely slow due to the large pathway gene-pair database.

In this article, we proposed a novel method called Dysregulated Pathway Identification Analysis (DysPIA) to overcome these shortcomings. A pathway is represented by the regulated gene pairs, but not just a set of genes, which is used in the traditional pathway analysis. We adopted the idea of CILP into analysis and performed a fast GSEA-like enrichment analysis. First, we calculated a Dysregulated Gene Pair Score (DysGPS) for each gene pair of interest, which was an individual-level-based statistic instead of population-level. Then, we calculated the Dysregulated Pathway Score (DysPS) based on a GSEA-like formula. Lastly, permutation-based significant P-values were estimated and the BH-FDR adjustment was performed. Compared with the previous methods, DysPIA provided a much larger and proper gene-pair background, fully employed all the sample information, and gained more significant pathways with biological meanings at a faster running speed.

The R package “DysPIA” has been constructed and is publicly available on R CRAN1, and the R dataset package “DysPIAData” including gene-pair background and pathway list is also publicly available on R CRAN2. They are also available on GitHub3.

MATERIALS AND METHODS

Flowchart of DysPIA

The overall procedure of DysPIA consists of two parts. The first part calculates the dysregulated score for each gene pair, and the second part calculates the dysregulated score for each pathway and estimates significance. The details are shown in Figure 2.

---

1 https://cran.r-project.org/web/packages/DysPIA/index.html
2 https://cran.r-project.org/web/packages/DysPIAData/index.html
3 https://github.com/lemonwang2020
**FIGURE 2** The flowchart of DysPIA. In the left side, there are the input data, gene expression, combined background, and pathway gene list. From the gene expression data, the CILP-like gene pair scores are calculated, then the DysGPS and DysPS are calculated in the right side. The results are shown in the bottom.

**Part 1: Dysregulated Gene Pair Score (DysGPS) Calculation**

Firstly, for each gene, the gene expression was mean centered and scaled separately in each group, e.g., case or control. Let $x$ be the expression value of gene $X$ across individuals in a population sample, with mean $\bar{x}$ and variance $\sigma^2$. Standardization (z-score normalization) transforms were performed, such that the resulting distribution has a mean of 0 and a standard deviation of 1.

$$\tilde{x} = \frac{x - \bar{x}}{\sigma}$$

Secondly, for each gene-pair $X_i$ and $X_j$ from the combined-background set in sample $k$, the CILP-like statistic which was the product of these two genes' standardized expression values was defined as:

$$y_{i,j} = \tilde{x}_i \tilde{x}_j = \frac{(\tilde{x}_i - \bar{x}_i)(\tilde{x}_j - \bar{x}_j)}{\sqrt{\sigma_i^2 \sigma_j^2}}$$

where, $\tilde{x}_i$ and $\tilde{x}_j$ are the standardized expression values for genes $X_i$ and $X_j$ in sample $k$, respectively.

Lastly, the dysregulated gene-pair score (DysGPS) was calculated based on a two-sample Welch’s $t$-test between groups:

$$\text{DysGPS}_{i,j} = \frac{y_{i,j}}{s_{\tilde{x}}}$$

### Table 1: Dysregulated Gene Pair Score (DysGPS)

| Pathway   | DysGPS | $P$-value | FDR |
|-----------|--------|-----------|-----|
| Pathway 1 | DysGPS$_1$ | $pval_1$ | FDR$_1$ |
| Pathway 2 | DysGPS$_2$ | $pval_2$ | FDR$_2$ |
| ... | ... | ... | ... |
| Pathway M | DysGPS$_M$ | $pval_M$ | FDR$_M$ |
where, $s^2 = \frac{n_1^2}{n_1} + \frac{n_2^2}{n_2}$ is the standard deviation of $y_{i,j}$. Here $s^2$ is the unbiased estimator of the variance of $y_{i,j}$ in each of the two groups with $n_i =$number of participants in group L.

**Part 2: Dysregulated Pathway Score (DysPS) Calculation and Significance Estimation**

A pre-ranked pathway enrichment analysis pipeline was utilized to calculate the DysPS and estimate the significance.

- Step 1: Rank the N gene pairs in the combined-background set in descending order based on DysGPS to form a gene-pair list $L = \{gp_1, gp_2, \ldots, gp_N\}$.
- Step 2: Calculate DysPS for each pathway.

For a given pathway, gene pairs get different weights based on whether they are in the pathway. We evaluate the fraction of gene pairs not in pathway $P('miss')$ present up to a given position $i$ in $L$.

$$S_{hit}(P, i) = \sum_{gp_j \in P} \frac{|DysGPS_j|^p}{N_R}$$

$$S_{miss}(P, i) = \sum_{gp_j \notin P} \frac{1}{N_{miss}}$$

where, $N_R = \sum_{gp \in P} |DysGPS|^p$, $N_{miss}$ represents the number of gene pairs in the list L and not in the pathway P.

$$S_{max} = \max(S_{hit}(P, i) - S_{miss}(P, i))$$

$$S_{min} = \min(S_{hit}(P, i) - S_{miss}(P, i))$$

$$DysPS = \begin{cases} S_{max}, & |S_{max}| = |S_{min}| \\ S_{min}, & |S_{max}| < |S_{min}| \end{cases}$$

**Simulation Data**

To assess the power and performance of DysPIA, we performed several extensive simulations under various conditions. A total of 100,000 gene pairs were generated as background, and 1,000 pathways were generated in each simulation. For each gene pair, 100 case and 100 control samples were generated using the R package “MASS.”

Firstly, the gene-pair expression data was generated. A Bivariate Normal Distribution was supposed for each gene-pair expression:

$$(g_i, g_j) \sim BN ((0, 0)', \Sigma)$$

where, $\Sigma = \left(\begin{array}{cc} r_k & \rho_{gs} \\ \rho_{gs} & 1 \end{array}\right)$, $k = 1, 2$ for conditions 1 and 2.

In 100,000 gene pairs, 95,000 (95%) were set to be non-dysregulated and 5,000 (5%) were set to be dysregulated. In non-dysregulated gene pairs, the correlation coefficients for both conditions were set to be equal ($r_1 = r_2$) and they were randomly drawn from a uniform distribution between -1 and 1. In dysregulated gene pairs, five gradient correlation coefficient differences (0.4–0.8) between $r_1$ and $r_2$ were selected. In total, there were 10 groups of gain/loss of correlation dysregulated gene pairs with different degrees, which made them as much similar as we can to the real dysregulated gene pairs. The detailed gene-pair generations are shown in Table 1.

After the gene expression profiles of each gene pair $i$ and $j$ were generated, their product was set to be the gene-pair CILP score, and then the T-test-based DysGPS was calculated.

In the pathway generations, two parameters, the proportion of dysregulated gene pairs ($p_{dys}$) and the pathway size ($n_p$, number of gene pairs in a pathway), were designed. The five simulations with different proportions (20–60%) of dysregulated gene pairs were selected and compared. In each simulation, five different pathway sizes (20, 40, 60, 80, and 100) were selected, and 200 pathways were generated with each pathway size, respectively. Strong/weak dysregulated pathways and gain/loss of correlation dysregulated pathways were designed based on
different parameters. In total, for each simulation, 1,000 pathways were generated, and 100 of them were dysregulated. The detailed pathway generations with a selected pathway size are shown in Supplementary Table 1.

In each condition, the Receiver-Operating Characteristic (ROC) curves were drawn based on sensitivity and specificity. Then the ROC analysis was used to evaluate and compare the performance of the algorithm under various scenarios.

**Gene Expression Dataset**

Three gene expression datasets were used to evaluate the proposed method.

The first dataset was the p53 mutation data which detected gene expression in response to the status of transcription factor p53 in 50 NCI-60 cell lines with 17 cell lines carrying the native p53 status and 33 cell lines carrying the mutated p53 status (Oliiver et al., 2002). This expression dataset for 10,100 genes was downloaded from the GSEA website, and 6,835 genes were used in the following analysis after matching the gene names with HGNC official gene symbols (Braschi et al., 2019). This dataset was used to compare our proposed method with other methods.

The second dataset was the breast cancer relapse dataset (GSE2034) (Wang et al., 2005) downloaded from NCBI Gene Expression Omnibus. There were 14,208 gene expressions in 286 lymph-node negative breast cancer patients including 179 relapse-free patients (controls) and 107 distant metastasis patients (cases). The dataset was divided into two groups based on ER status. There were 209 samples in the “ER+” group, including 129 control samples and 80 case samples. There were 77 samples in the “ER−” group, including 50 control samples and 27 case samples. The results for ER+ and ER− were compared and literature verified.

The third dataset was an RNA-seq expression dataset for breast cancer patients with different subtypes in The Cancer Genome Atlas (TCGA) (Vasaikar et al., 2018). It contained 20,155 genes in 1,041 breast cancer patients (40 normal breast samples were excluded). There were four breast cancer subtypes (Luminal-A, Luminal-B, Basal-like, HER2-enriched) based on the PAM50 model (Cancer Genome Atlas Network, 2012). There were 560

**Background Gene-Pair Set and Pathway List**

There were 19,297 genes in HGNC (Braschi et al., 2019) (version 01/31/2020), and it was impractical to use all possible gene pairs (>372 million) to be the background dataset. Therefore, a representative subset was critical in the pathway analysis. A combined background was proposed in DysPIA, including two parts. The first part was the retrieved gene pairs in the pathways from public pathway databases, and the second part was the randomly selected gene pairs.

For each pathway, only the regulated gene pairs are considered. It is significantly different to GSCA, GSNCA, and IB-GSA which simply include all n(n-1)/2 gene pairs. Based on the R package “graphite” (Sales et al., 2012, 2019), direct gene–gene regulations and metabolite-based propagated gene–gene regulations were retrieved from the pathways in eight public pathway databases for Homo Sapiens (version 01/31/2020), which are Reactome (Matthews et al., 2009), KEGG (Ogata et al., 1999), BioCarta (Nishimura, 2001), Panther (Mi et al., 2013), PathBank (Wishart et al., 2020), NCI/Nature Pathway Interaction Database (Schaefer et al., 2009), SMPDB (Jewison et al., 2014), and PharmGKB (Whirl-Carrillo et al., 2012). Totally, there were 333,484 gene pairs in 99,984 pathways. The details are shown in Table 2.

These 333,484 gene pairs formed the first part of the background set, which was called the observed background gene-pair set. To avoid redundancy and easily query gene pairs in the database, in each gene pair, the genes were arranged in ascending order based on gene symbols, i.e., the first gene was smaller than the second one.

A total of 700,000 gene pairs were randomly selected from 19,297 genes in HGNC, and 349,915 of them in ascending order (about half of the selected gene pairs) remained as the random background gene-pair set. There were 982 gene pairs in common (about half of the selected gene pairs) remained as the random background gene-pair set. There were 982 gene pairs in common (about half of the selected gene pairs) remained as the random background gene-pair set.

Finally, their combination with 682,417 gene pairs was set to be

**TABLE 1** The simulation data with 100,000 gene pairs.

| Gene pair | Number of gene pairs | Correlation coefficients |
|-----------|----------------------|--------------------------|
| GCDG      | 500                  | $r_1 \sim U[-0.6, 1], r_2 = r_1 - 0.4$ |
|           | 500                  | $r_1 \sim U[-0.5, 1], r_2 = r_1 - 0.5$ |
|           | 500                  | $r_1 \sim U[-0.4, 1], r_2 = r_1 - 0.6$ |
|           | 500                  | $r_1 \sim U[-0.3, 1], r_2 = r_1 - 0.7$ |
|           | 500                  | $r_1 \sim U[-0.2, 1], r_2 = r_1 - 0.8$ |
| NDG       | 95,000               | $r_1 = r_2 \sim U[-1, 1]$ |
|           | 500                  | $r_1 \sim U[-1, 0.6], r_2 = r_1 + 0.4$ |
|           | 500                  | $r_1 \sim U[-1, 0.5], r_2 = r_1 + 0.5$ |
|           | 500                  | $r_1 \sim U[-1, 0.4], r_2 = r_1 + 0.6$ |
|           | 500                  | $r_1 \sim U[-1, 0.3], r_2 = r_1 + 0.7$ |
|           | 500                  | $r_1 \sim U[-1, 0.2], r_2 = r_1 + 0.8$ |

GCDG, gain of correlation dysregulated gene pair; NDG, non-dysregulated gene pair; LCDG, loss of correlation dysregulated gene pair.

**TABLE 2** Summary of pathways and gene pairs.

| Database name | Number of pathways | Number of gene pairs |
|---------------|--------------------|----------------------|
| Reactome      | 1,901              | 264,867              |
| KEGG          | 306                | 60,571               |
| BioCarta      | 247                | 5,421                |
| Panther       | 84                 | 12,951               |
| PathBank      | 48,593             | 6,882                |
| NCI           | 212                | 14,198               |
| SMPDB         | 48,581             | 6,777                |
| PharmGKB      | 60                 | 2,727                |
| Total pathways| 99,984             | 333,484              |
| Random background | NA               | 349,915              |
| Combined background | NA         | 682,417              |
FIGURE 3 | ROC curves in simulation study. (A) ROC curves in the five simulations with different proportions (20–60%) of dysregulated gene pairs. (B) ROC curves of pathways with different sizes (20, 40, 60, 80, and 100) when the proportion of dysregulated gene pairs is 20%. The group “Pathways with all sizes” means the union set of pathways with different sizes (20, 40, 60, 80, and 100). (C–F) Similar to (B), ROC curves of pathways when the proportions of dysregulated gene pairs are 30–60%, respectively.

the final background, which was called the combined background gene-pair set. In this combined background, there were similar numbers of gene pairs in the observed background and random background. The evaluation of the combined background is shown in section “Gene-Pair Background Evaluation.”

In total, there were 99,984 pathways retrieved which can be used in DysPIA. The KEGG pathways were used as examples in the following analysis.

RESULTS

Simulation

The Receiver-Operating Characteristic (ROC) analysis was used to evaluate and compare the performance of the algorithm under various scenarios (Figure 3). The area under the ROC curve (AUC) was calculated as the measure for comparison. Firstly, we compared the ROC and AUC among groups with different $p_{\text{dysgp}}$ (Figure 3A). The overall AUC ranged from 0.9584 to 0.9896 and the AUC increased when the $p_{\text{dysgp}}$ increased. Then within each $p_{\text{dysgp}}$ group, the subgroups of different $n_p$ were compared (Figures 3B–F). The AUC increased when the pathway size increased for all the subgroups, and the AUC reached nearly 1 when there were 80 or more gene pairs in the pathway.

This simulation study indicated that DysPIA was able to identify the causal pathways with strong sensitivity and specificity.

Gene-Pair Background Evaluation

The gene-pair background was evaluated based on p53 data. $\text{DysGPS}$ was calculated in the observed background and random background separately, then the absolute scores were compared between these two groups using the Student T-test. The results showed that there were significant differences between them (mean absolute scores: 0.8150 vs. 0.8395, $P$-value: 2.14e-12). Therefore, the observed background was not good enough to be representative of the whole background, and the combined background was more real and critical.

Then we evaluated the sufficiency and the robustness of the sampling procedure since it was only about 1% of the whole gene pairs. We repeated the sampling procedure 20 times (randomly selected 700,000 gene pairs 10 times and 7,000,000 gene pairs 10 times). Then, $\text{DysGPS}$ was calculated, and the absolute scores were compared between these groups using the Student T-test. The results showed that there were significant
differences between the observed background group and each random background group (all \(P\)-values < 1e-10); no significant difference between the random background groups with 700,000 gene pairs and the random background groups with 7,000,000 gene pairs; and only 7 significant differences among the random background groups with 7,000,000 gene pairs under the threshold \(P\)-value < 0.05. The proportion of significant results is lower than the significance level (7/190 = 0.0368 < 0.05). Based on these results, we would say that this sampling procedure is robust. The detailed results are shown in Supplementary Table 2.

To evaluate the sufficiency of this combined background, we performed DysPIA using the whole background and compared it with the result using the proposed combined background. Based on the whole background, it took about 10 h to get the result with only 1,000 permutations, and we did not get the result with 10,000 permutations due to the large computational load, which indicated that it was impractical considering the whole background. The results using 1,000 permutations showed high consistency between the whole background and the combined background. The Pearson/Spearman correlation coefficient between them was 0.9973/0.9974. Sixteen pathways were significantly enriched under the threshold \(P\)-value < 0.01, and all of them were in the significant result based on combined background (17 pathways). The only pathway which was significant in the result based on combined background but not in whole background was “Cellular senescence.” Its \(P\)-value was 0.0112 which was close to the significant level. The detailed results are shown in Supplementary Table 3.

Based on these results, we would say that using a limited set of random gene pairs is as good as using the whole background.

**Computational Speed and Consistency**

Since there was no public resource for IB-GSA, we compared DysPIA with ESEA, GSCA, and GSNCA.

In DysPIA, the idea of fast calculation proposed in FGSEA (Korotkevich et al., 2019) was applied to shorten the running time of the program. In p53 data, DysPIA ran significantly faster than others. Using the same personal computer (MacBook Pro, macOS Catalina, i5 2.7 GHz, 8G DDR3 memory), it took about 1.82 s for 1,000 permutations while the others took 23.80 min to 2.03 h (~800–4,000 times slower). When increasing to 10,000 permutations, the difference became much greater (~1,700–8,000 times). The details are shown in Figure 4.

The results of DysPIA with fast procedure were also compared to the regular calculation while keeping all the other steps the same. The Pearson (Spearman) correlation coefficient of \(P\)-values between them was 0.9827 (0.9825) under 1,000 permutations. Therefore, DysPIA with fast calculation kept high consistency with the regular method while it was much faster.

**Number of Permutations**

Different numbers of permutations were compared in all the methods based on p53 data. The Pearson (Spearman) correlation coefficients of \(P\)-values between 1,000 and 10,000 permutations are shown in Table 3. In DysPIA, GSCA, and GSNCA, the correlation coefficients were around 0.998 while they were around 0.90 in ESEA. We further compared the results among 1,000, 10,000, and 100,000 permutations using DysPIA (Supplementary Table 3). Firstly, there was no difference among them if a threshold \(P\)-value < 0.01 was used. We got exactly the same 17 significant pathways using 1,000, 10,000, or 100,000 permutations. Secondly, 10, 9, and 10 significant pathways were identified if a threshold FDR < 0.05 was used. Nine of these pathways were the same, and pathway “Morphine addiction” can be identified in the 1,000 and 100,000 permutation groups (FDR = 0.0323 and 0.0267), but not in the 10,000 permutation group (FDR = 0.0598, close to the significant level 0.05). Thirdly, some \(P\)-values and FDRs
were significantly different among them due to the precision of different permutations. For example, P-values of pathway “Graft-versus-host disease” were 0.0002, 0.0002, and 2.01e-05 (FDRs: 0.0159, 0.0188, and 0.0024) in 1000, 10,000 and 100,000 permutations; P-values of pathway “Antigen processing and presentation” were 0.0002, 0.0002, and 2.02e-05 (FDRs: 0.0159, 0.0188, and 0.0024) in 1000, 10,000, and 100,000 permutations. In these two pathways, the enrichment scores (ES) based on the real data were lower than all the ES based on permutation, and the P-values were significantly different among different permutations due to different precisions. These results indicated that the numbers of permutations could affect the P-values and FDRs and the 1,000 permutation was not good enough while a large number of pathways were tested. Ten thousand or more permutations were recommended, and it was still very fast in DysPIA. The following results were based on 10,000 permutations.

**Comparison Between DysPIA and Other Methods**

We compared the results of these methods based on p53 data. As shown in Table 4, there were low correlations between these methods. The Pearson (Spearman) correlation coefficients of the P-values among ESEA, GSCA, and GSNCA were pretty low (−0.03−0.05), and the correlation coefficients between DysPIA and ESEA/GSCA were just a little higher (0.10~0.19).

When the significant threshold was set to FDR < 0.05, there were 10 significant dysregulated pathways in DysPIA (the top 10 items in Supplementary Table 4). However, there was no significant pathway in ESEA, GSCA, or GSNCA under FDR < 0.05. Then the significant threshold was relaxed to p < 0.01; there were 17, 7, 1, and 1 significant dysregulated pathways in DysPIA, ESEA, GSCA, and GSNCA, respectively, and only one in common between DysPIA and ESEA. The detailed results of DysPIA, ESEA, GSCA, and GSNCA are shown in Supplementary Tables 4–7, respectively.

The significant dysregulated pathways were further literature verified. In DysPIA, 16 out of 17 pathways were verified by previous studies (94.1%), while five out of seven pathways in ESEA could be verified (71.4%). The significant dysregulated pathways identified by GSCA and GSNCA were also verified. Specifically, in this p53 mutation study, pathway “p53 signaling pathway” can only be identified in DysPIA. These results showed that DysPIA can mine more dysregulated pathways with a high confidence.

**Dysregulated Pathways in Breast Cancer Relapse**

The dysregulated pathways in breast cancer relapse with different ER status were identified based on the dataset GSE2034 using the DysPIA method. Under the threshold of FDR < 0.05, there were 14 and 6 significant dysregulated pathways in the “ER+” group and “ER−” group, respectively (Supplementary Tables 8, 9). However, there was only one pathway (antigen processing and presentation) in common, which meant the mechanisms of breast cancer relapse were quite different between the two groups with different ER status. The literature verification was performed on these significant pathways. In the ER+ group, 13 out of 14 pathways (92.9%) had been verified by the existing studies, and 5 out of 6 (83.3%) in the ER− group (Supplementary Tables 8, 9).

**Dysregulated Pathways Between Breast Cancer Subtypes**

For each pair of subtypes, the number of significant dysregulated pathways (FDR < 0.05 and FDR < 0.01) are listed in Table 5. The smaller the number, the more similar between the two subtypes.

Subtypes Her2 and LumB were much closer than others, followed by LumA and LumB, while subtype Basal was much different from others. These results were consistent with the previously reports based on PAM50 gene expression (Bastien et al., 2012; Hu et al., 2013; Wallden et al., 2015).

To test the robustness of the proposed method, 80% of the samples in each subtype were randomly selected and used to identify dysregulated pathways by DysPIA. Then, the FDRs were compared to the results using the whole dataset based on correlation analyses. This process was repeated for five times. The average Pearson (Spearman) correlation coefficient was around 0.8, which showed the robustness of DysPIA. The detailed results are shown in Supplementary Tables 10, 11.

| Method | PCC | SCC |
|--------|-----|-----|
| DysPIA | 0.9986 | 0.9983 |
| ESEA | 0.9064 | 0.9037 |
| GSCA | 0.9982 | 0.9976 |
| GSNCA | 0.9986 | 0.9981 |

**TABLE 3** | The correlation coefficients of P-value between 1,000 and 10,000 permutations.

| Method | PCC | SCC |
|--------|-----|-----|
| DysPIA | 0.1900 | 0.1138 | −0.1011 |
| ESEA | 0.9671 | 0.0516 | −0.0308 |
| GSCA | 0.0583 | 0.0531 | 0.0150 |
| GSNCA | −0.1100 | −0.0308 | 0.0222 | 1 |

The upper triangle above the diagonal (number 1) in Table 4 is the Pearson correlation coefficient, and the lower triangle under the diagonal is the Spearman correlation coefficient.
**DISCUSSION**

Compared to DE and DV, DC/dysregulation analysis considers the dysregulation of two genes between different conditions. Therefore, the DC-based pathway analysis considered the gene regulation relationships while most DE and DV-based methods did not. DC-based pathway analysis can identify some significant dysregulated pathways related to the phenotype interest with different mechanisms to the significant related pathways identified by DE and DV methods.

In DysPIA, the idea of CILP was adopted. There was a score for each sample and gene pair, then a T-test-based statistic was used to represent the gene-pair dysregulation level. In this analysis, the full sample information was used, and sample sizes of different conditions were considered in the calculation. On the other hand, in the PCC-based methods, the PCC was first calculated, and the sample sizes were not considered.

There were regulations or some other relationships between gene pairs in the pathways, which means they were not randomly selected. We compared the absolute dysregulated scores between two groups, the observed gene-pair set from pathways, and the randomly selected gene pairs. The results confirmed that there was a significant difference between them. Therefore, the combined gene-pair background was much sufficient than the observed gene pairs from pathways only. DysPIA was much faster thanks to the fast calculation algorithm for pre-ranked data, and the results confirmed the consistence between the fast method and the classic method.

Unfortunately, there were only a few common pathways identified from different methods. There are several possible reasons. The first was that the gene regulations were not fully considered in GSCA and GSNCA. In their analyses, the test statistic was based on all the possible gene pairs between genes in each pathway. Therefore, the priori regulation knowledge in pathways was not considered but just considered the pathways as gene sets. DysPIA and ESEA considered the existed gene pairs in the pathways in the analysis. The second was that there were different measures in different methods. While PCC or similar measures were used in most methods, the MI-based Edge Score in ESEA was novel but has less directly biological meaning. In p53 mutation data, DysPIA identified more significant dysregulated pathways than other methods under the same threshold with high literature validation rate. The pathway “p53 signaling pathway” can only be identified by DysPIA. In the application of breast cancer relapse dataset and breast cancer subtype dataset, DysPIA also identified several dysregulated pathways which can be verified. Both the simulation and real data results showed that DysPIA is effective and has a great biological significance.

**CONCLUSION**

In DysPIA, the gene regulation information in the pathway is considered, and it provides new insight into pathway analysis area. Both in simulation study and in real datasets, the results show that DysPIA is effective and fast and has a great biological significance. However, there are only a few common pathways identified from different methods. Therefore, using different types of pathway analysis, methods are recommended so that more accurate risk pathways will be identified. The R package “DysPIA” has been constructed and is publicly available on R CRAN at https://cran.r-project.org/web/packages/DysPIA/index.html. Another R dataset package “DysPIAD” containing the latest gene-pair background and pathway list has been publicly available on R CRAN at https://cran.r-project.org/web/packages/DysPIAD/index.html.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

**AUTHOR CONTRIBUTIONS**

LW, JL, and XL: conceptualization. KL and JL: methodology. LW and WX: software and data curation. WX and ZW: validation. JL: resources. LW, KL, WX, and ZW: writing—original draft preparation. XL, WF, and JL: writing—review and editing. All authors have read and agreed to the published version of the manuscript.

**FUNDING**

This work was supported by the Hainan Provincial Natural Science Foundation of China (820RG637), the Major Science and Technology Program of Hainan Province (ZDKJ202003), China National Natural Science Foundation (61471139, 31701159), and HEU Fundamental Research Funds for the Central University (3072020CFT0401).

**ACKNOWLEDGMENTS**

The authors thank Dr. Hui Yu (University of New Mexico) for her contribution in the model construction.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2021.647653/full#supplementary-material

**Supplementary Table 1** | Simulated pathways with a selected sample size in simulation study.

**Supplementary Table 2** | P-values of t-test among the absolute DysGPS scores from different backgrounds.

**Supplementary Table 3** | DysPIA results on p53 data with different backgrounds.

**Supplementary Table 4** | Significant dysregulated pathways by DysPIA on p53 data ($p < 0.01$).

**Supplementary Table 5** | Significant dysregulated pathways by ESEA on p53 data ($p < 0.01$).
References

Auffray, C., Chen, Z., and Hood, L. (2009). Systems medicine: the future of medical genomics and healthcare. Genome Med 1, 2. doi: 10.1186/gm2

Barry, W. T., Nobel, A. B., and Wright, F. A. (2005). Significance analysis of functional categories in gene expression studies: a structured permutation approach. Bioinformatics 21, 1943–1949. doi: 10.1093/bioinformatics/bti260

Bastien, R. R., Rodriguez-Lescure, A., Ebbert, M. T., Prat, A., Munarriz, B., Rowe, L., et al. (2012). PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics 5:44. doi: 10.1186/1755-7909-5-4

Benjamini, Y., and Hochberg, Y. (1995). Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society. Series B (Methodological) 57, 289–300. doi: 10.1111/j.2517-6161.1995.tb02031.x

Braschi, B., Denny, P., Gray, K., Jones, T., Seal, R., Tweedie, S., et al. (2019). Genenames.org: the HGNC and VGNC resources in 2019. Nucleic Acids Res 47, D786–D792.

Cancer Genome Atlas Network (2012). Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70. doi: 10.1038/nature11412

Choi, Y., and Kendziorski, C. (2009). Statistical methods for gene set co-expression analysis. Bioinformatics 25, 2780–2786. doi: 10.1093/bioinformatics/btp502

Cui, X., and Churchill, G. A. (2003). Statistical tests for differential expression in cDNA microarray experiments. Genome Biol 4, 210.

Efрон, B., and Tibshirani, R. (2007). On testing the significance of sets of genes. JASA 102, 1274–1285.

Han, J., Shi, X., Zhang, Y., Xu, Y., Jiang, Y., Zhang, C., et al. (2015). ESEA: Discovering the Dysregulated Pathways based on Edge Set Enrichment Analysis. Sci Rep 5, 13044.

Hardcastle, T. J. (2016). Generalized empirical Bayesian methods for discovery of differential data in high-throughput biology. Bioinformatics 32, 195–202.

Hardcastle, T. J., and Kelly, K. A. (2010). baySeq: empirical Bayesian methods for identifying differential expression in sequence count data. BMC Bioinformatics 11:422. doi: 10.1186/1471-2105-11-422

Ho, J. W., Stefani, M., dos Remedios, C. G., and Charleston, M. A. (2008). Differential variability analysis of gene expression and its application to human diseases. Bioinformatics 24, 1390–1398.

Hu, Y., Bai, L., Geiger, T., Goldberger, N., Walker, R. C., Green, J. E., et al. (2013). Genetic background may contribute to PAM50 gene expression breast cancer subtype assignments. PloS One 8:e72287. doi: 10.1371/journal.pone.0072287

Huang da, W., Sherman, B. T., and Lempicki, R. A. (2009a). Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37, 1–13. doi: 10.1093/nar/gkn923

Huang da, W., Sherman, B. T., and Lempicki, R. A. (2009b). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4, 44–57. doi: 10.1038/nprot.2008.211

Jewison, T., Su, Y., Disfany, F. M., Liang, Y., Knox, C., Maciejewski, A., et al. (2014). SMPDB 2.0: big improvements to the Small Molecule Pathway Database. Nucleic Acids Res 42, D478–D484.

Kanehisa, M., Gotz, S., Sato, Y., Furumichi, M., and Tanabe, M. (2012). KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res 40, D109–D114.

Kim, S. Y., and Volsky, D. J. (2005). PAGE: parametric analysis of gene set enrichment. BMC Bioinformatics 6:144.

Korotkevich, G., Sukhor, V., and Sergushichev, A. (2019). Fast gene set enrichment analysis. bioRxiv [Preprint] bioRxiv: 060012
Wang, Y., Klijn, J. G., Zhang, Y., Sieuwerts, A. M., Look, M. P., Yang, F., et al. (2005). Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. *Lancet* 365, 671–679. doi: 10.1016/s0140-6736(05)17947-1

Whirl-Carrillo, M., McDonagh, E. M., Hebert, J. M., Gong, L., Sangkuhl, K., Thorn, C. F., et al. (2012). Pharmacogenomics knowledge for personalized medicine. *Clin Pharmacol Ther* 92, 414–417.

Wishart, D. S., Li, C., Marcu, A., Badran, H., Pon, A., Budinski, Z., et al. (2020). PathBank: a comprehensive pathway database for model organisms. *Nucleic Acids Res* 48, D470–D478.

Yu, H., Liu, B. H., Ye, Z. Q., Li, C., Li, Y. X., and Li, Y. Y. (2011). Link-based quantitative methods to identify differentially coexpressed genes and gene pairs. *BMC Bioinformatics* 12:315. doi: 10.1186/1471-2105-12-315

Zhang, J., Li, J., and Deng, H. W. (2009). Identifying gene interaction enrichment for gene expression data. *PLoS One* 4:e8064. doi: 10.1371/journal.pone.0008064

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Copyright © 2021 Wang, Xie, Li, Wang, Li, Feng and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**